A phase I/II study of Lonsurf combined with Oxaliplatin in metastatic colorectal cancer patients refractory to standard chemotherapy.
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2631090
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Lonsurf/L-OHP therapy Lonsurf: 70mg/m2, d1-5, d15-19 (fixed dose) L-OHP: 50-85mg/m2, d1,d15 (dose escalation) every 4 weeks
Primary outcome(s): [Phase I part] To determine recommended dose (RD) and maximum tolerated dose (MTD) [Phase II part]Disease Control Rate (DCR)
Study Design: Single arm Non-randomized
创建时间：
2014-12-15
